-
Real-world patient survey data shows negative impact of nocturia
in Uncategorized onNew patient survey data presented today at the European Association of Urology (EAU 14) congress, showed that nocturia…
0 -
MSD, Ferring Pharmaceuticals and the World Health Organization – Working Together to Prevent Excessive Bleeding in Women after Childbirth
in Uncategorized onFerring Pharmaceuticals and MSD, known as Merck in the United States and Canada, today announced their collaboration with the World Health…
-
New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists
in Uncategorized onA paper published today in European Urology, the official journal of the European Association of Urology, indicates that the gonadotropin…
-
Ferring Pharmaceuticals appoints Alex Chang Senior Vice President, Asia Pacific
in Uncategorized onFerring Pharmaceuticals announced today that it has appointed Alex Chang to head the company’s Asia Pacific region effective 1 November 2013…
-
MISODEL™, Ferring’s removable misoprostol vaginal delivery system, approved for labour induction in European Decentralised Procedure
in Uncategorized onFerring Pharmaceuticals announced today that its MISODELTM (misoprostol) removable, controlled-release vaginal delivery system for labour induction…
-
Ferring announces second $3 million donation to the Royal Textile Academy of Bhutan
in Uncategorized onFerring Pharmaceuticals has announced a second $3 million donation to the Royal Textile Academy of Bhutan to support its mission to preserve and…
-
Ferring presents phase III data for a controlled release misoprostol vaginal delivery system for labour induction at the First European Congress on Intrapartum Care
in Uncategorized onData from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated…
-
Ferring Pharmaceuticals begins phase III trials of elobixibat, new compound with novel mechanism of action for chronic idiopathic constipation
in Uncategorized onFerring Pharmaceuticals today announced it has initiated enrolment of patients in two phase III clinical trials…
-
Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting
in Uncategorized onThe following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego…
-
New data highlight considerable burden of Nocturia
in Uncategorized onNew data presented today at the European Association of Urology (EAU) congress show that nocturia (waking up one or more times to void at night)…
Uncategorized
Uncategorized